

BRCA1 Expression Status in Relation to DNA Methylation of the BRCA1 Promoter Region in Sporadic Breast Cancers

Youko Niwa, Tetsunari Oyama and Takashi Nakajima

Second Department of Pathology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511

To understand the biological role of BRCA1 in sporadic breast cancers, the relationship between DNA methylation of the BRCA1 promoter region and BRCA1 expression was studied using molecular biological and immunohistochemical methods. Furthermore, BRCA1 expression was compared with the expression of various cell cycle regulatory proteins and the morphological nuclear grade of cancer cells. Of 32 sporadic breast cancers investigated in this study, 10 (31%) revealed DNA methylation of the BRCA1 promoter region. The expression of BRCA1 was observed in the nuclei of cancer cells and 18 (56%) of 32 cancers were positive for BRCA1 immunoreactivity. Breast cancers with BRCA1 methylation lacked BRCA1 expression, except for only three cancers, and there was a significant inverse relationship between BRCA1 methylation and its expression in sporadic breast cancers (P=0.043). Compared with the expression of various cell cycle regulatory proteins, breast cancers with BRCA1 methylation showed decreased expression of estrogen receptor (P=0.016) and p27 (P=0.018) and increased expression of p21 (P=0.011). Furthermore, breast cancers without BRCA1 expression or with BRCA1 methylation had a tendency to contain nuclei with higher grade. These findings indicate that BRCA1 methylation might greatly influence its expression and BRCA1 expression might play an important role in cell cycle regulation and influence the grade of malignancy of sporadic breast cancers.

Key words: BRCA1 — Expression — Immunohistochemistry — DNA methylation — Sporadic breast cancers

BRCA1 has been identified by positioning cloning methods as a strong candidate for the 17q-linked gene for familial breast cancers and has been linked to more than 45% of familial breast cancers and 80% of families with breast and ovarian cancer.1) BRCA1 is a putative tumor suppressor gene located on chromosome 17q21 and spans 100 kb of genomic DNA, which encodes a protein of 220 kD consisting of 1863 amino acids.3) The BRCA1 protein is mainly localized in cell nuclei and is phosphorylated in a cell cycle-dependent manner.5) As regards subcellular nuclear localization, the BRCA1 protein has been reported to colocalize with Rad51, a homolog of bacterial RecA, in S phase cells,3) which suggests a role for BRCA1 in the control of recombination and of genome integrity. However, the exact biological function of BRCA1 still remains unclear.

More than 300 germline mutations have been identified so far in patients with familial breast and/or ovarian cancer.4)12 These mutations are distributed across the entire coding region of the BRCA1 gene, and the majority is predicted to result in truncated proteins or loss of a BRCA1 transcript. Therefore, mutations in the BRCA1 gene may play a significant role in the tumorigenesis of familial breast cancer.5)6) Though it has been shown that BRCA1 mRNA levels are reduced or absent in both sporadic and familial breast cancer,7,8) a few somatic mutations in the BRCA1 gene have been identified in sporadic breast cancers.9) From these studies, the decreased expression of BRCA1 in sporadic breast cancer is thought to be caused by mechanisms other than somatic mutation of BRCA1.

Recently, it has become clear that gene expression is regulated by CpG methylation in the promoter region, for instance, of several tumor suppressor genes Rb, p15, p16, and VHL.10–14) In 1997, Dobrovic and Simpfendorfer first reported methylation of the BRCA1 gene in sporadic breast cancers.15) The following year, Mancini et al. reported that CpG methylation of the BRCA1 gene was tumor-specific and involved a putative CREB binding site.16) These findings have suggested that decreased expression of BRCA1 in sporadic breast cancer might be attributed to down-regulation by CpG methylation in the 5′ regulatory region of the BRCA1 gene. However, there is still controversy over the occurrence of inactivation of BRCA1 by hypermethylation of its promoter.17)

In the present study, the relationship between BRCA1 protein expression and methylation status of the BRCA1 gene was investigated in 32 cases of sporadic breast cancer. In order to know the function of BRCA1 protein, the expression status of several cell cycle regulatory proteins was immunohistochemically studied in these breast can-
cers.\textsuperscript{18) Then the expression of the BRCA1 protein was compared with immunohistochemical findings of cyclin D1, p53, p16, p21 and p27, in addition to the expression of estrogen receptor and the histological nuclear grade of breast cancer.

MATERIALS AND METHODS

Materials Thirty-two breast cancer patients without any family history of breast cancer were randomly selected and used in this study. Breast cancer patients underwent surgery at Gunma University Hospital and Motojima General Hospital (Ohta, Gunma), and both cancerous and non-cancerous tissues were freshly obtained at operation and kept frozen at \(-80^\circ\text{C}\) until the BRCA1 gene methylation analysis. The remaining breast cancer tissues were fixed in 15\% formalin and embedded in paraffin for routine pathological examination and various immunohistochemical studies. Using hematoxylin eosin-stained slides, the nuclear grade of all breast cancers was re-evaluated based on the histological criteria for breast carcinoma of the Japanese National Surgical Adjuvant Study of Breast Cancer (NSAS-BC), Pathology Section.\textsuperscript{19, 20) DNA methylation analysis of the BRCA1 gene From 32 frozen cancerous and non-cancerous tissues, each DNA was purified using the conventional phenol-chloroform method after homogenization and proteinase K digestion. The amount of DNA was quantified by absorbance measurements at 260 nm (UV). For the detection of methylation status in the BRCA1 gene, each DNA obtained from both cancerous and non-cancerous tissues was digested with HhaI (TaKaRa, Otsu, Shiga) overnight, followed by amplification of the BRCA1 gene using polymerase chain reaction (PCR), as illustrated in Fig.1.\textsuperscript{21) As a negative control of DNA methylation in the BRCA1 gene, purified DNA from MCF7 breast cancer cells was used in this study. The primer pair for the amplification of the BRCA1 gene (Fig. 1) was as follows: sense primer (1695 to 1675) 5'-AATCCAGAGCCCCGAGAGACGC-3'; anti-sense primer (1436 to 1456) 5'-GGTTTCCGTGGCAACGGAAAAAGCC-GC-3'. Total volume of the PCR mixture was 10 \(\mu\text{L}\), containing 10 ng of template DNA, 200 \(\mu\text{M}\) of each deoxyribonucleoside triphosphate, 1 \(\mu\text{M}\) of each primer, 1 \(\mu\text{L}\) of 10× PCR buffer (Perkin Elmer, Branchburg, NJ) and 1 \(\mu\text{L}\) (5 U) of AmpliTaq DNA Polymerase (Perkin Elmer) and the PCR reaction was carried out for 28 cycles under the following conditions: 94\°C/30 s for denaturing, 60\°C/30 s for annealing and 72\°C/30 s for extension after the first denaturation at 94\°C for 1 min, and final extension was performed at 72\°C for 7 min. The PCR products were electrophoresed on 8\% polyacrylamide gel and the bands were visualized using ethidium bromide staining. This DNA fragment of 259 \(\text{bp}\) contained three methylation-sensitive HhaI sites (Fig. 1). To examine whether the amplified PCR product was exactly the same as the 5\‘ prime region of the BRCA1 gene, the amplified 259 \(\text{bp}\) fragment was digested by two restriction enzymes, SacI and AfaI, whose sites are located in this DNA region. The PCR products digested by SacI and AfaI showed 168 and 205 \(\text{bp}\) bands on electrophoresis, respectively (Fig. 2). The methylation status in the BRCA1 gene was determined by observing whether the band specific to the BRCA1 gene could be amplified by PCR after digestion of breast cancer DNA with HhaI restriction enzyme.

Immunohistochemistry For the immunohistochemical study, 3 \(\mu\text{m}\) thick sections were cut from paraffin blocks which contained representative histology of the breast cancer. Paraffin sections on silane-coated slides were dewaxed with xylene and rehydrated through a graded alcohol series. Then, endogenous peroxidase activity was blocked in absolute methanol solution containing 0.3\% hydrogen peroxide for 30 min and the slides were washed in 10 mM

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig2.png}
\caption{PCR amplification of the promoter region and exon 1a of BRCA1 containing AfaI and SacI sites. PCR product was shown to contain the promoter region and exon 1a of BRCA1. M: DNA size marker (\(\varphi_{174}/\text{HaeIII}\)). Lane 1: The PCR product of the promoter region and exon 1a of BRCA1 was 259 \(\text{bp}\) in size. Lane 2: After digestion of the 259 \(\text{bp}\) PCR product by AfaI, the product was shown to be 205 \(\text{bp}\) in size. Lane 3: After digestion of 259 \(\text{bp}\) PCR product by SacI, the product was shown to be 168 \(\text{bp}\) in size.}
\end{figure}
phosphate-buffered saline (PBS), pH 7.4. For antigen retrieval, they were immersed in appropriate solutions such as 1 mM EDTA, 0.1 mM citrate-phosphate buffer or 20% zinc sulfate solution, and microwaved at 90°C for 10 min (Bio-Rad Laboratories, Hercules, CA). After the buffer had cooled, normal horse serum was reacted with the slides for 30 min to eliminate non-specific immunostaining. Then the slides were reacted with various primary antibodies overnight at 4°C in a humidified chamber. The details of the primary antibodies used in this study were as follows: monoclonal antibody (mAb) Ab-1 for BRCA1 with a dilution of 1:50 (Oncogene Research Products Calbiochem, Cambridge, UK), mAb for estrogen receptor (ER) with a dilution of 1:8 (Immunotech, Marseille, France), mAb DO7 for p53 protein with a dilution of 1:100 (Novocastra, Newcastle, UK), mAb NCL-WAF1 for p21 with a dilution of 1:40 (Novocastra), mAb cyclin D1 with a dilution of 1:50 (Novocastra), mAb p27 with a dilution of 1:5000 (Transduction Lab., Lexington, KY) and mAb JC8 for p16 with a dilution of 1:500 (kindly provided by Dr. J. Koh, Massachusetts General Hospital). After the reaction of each primary antibody, the slides were reacted with biotinylated anti-mouse antibody for 30 min at room temperature followed by streptavidin with a dilution of 1:500 (Dako, Glostrup, Denmark). Finally, the slides were stained using the 3,3’-diaminobenzidine tetrahydrochloride solution and were counterstained lightly using hematoxylin.

For immunohistochemical evaluation of BRCA1, nuclear immunostaining of tumor cells was compared with that of normal mammary duct cells. If more than 50% of tumor cell nuclei showed the same or stronger immunoreactivity than that of normal mammary duct cells, it was evaluated as positive (+). For each immunohistochemical evaluation of p53, p21, p27, the frequency of nuclear immunostaining, negative or less than 5%, 5% to 50% and more than 50% were evaluated as negative (−), positive (+) and strongly positive (+++), respectively. In p16 and cyclin D1, more than 50% of tumor cells with nuclear staining were evaluated as positive (+) and in ER, more than 10% of tumor cells with nuclear staining were evaluated as positive (+).

Statistical analysis. All statistical analyses were performed using the χ2 test. A P value less than 0.05 was considered to be statistically significant.

RESULTS

DNA methylation analysis of the BRCA1 gene. As shown in Fig. 1, the PCR system could amplify a 259 bp DNA fragment containing the 5’ prime region of the BRCA1 gene, including its promoter area.

The PCR system amplified the 259 bp fragment band from all DNA samples purified from cancerous and non-cancerous breast tissues without digestion by HhaI (Fig. 3). To detect the methylation status of the BRCA1 gene, the PCR was carried out on DNAs purified from cancerous and non-cancerous breast tissues after HhaI digestion. The PCR failed to detect any 259 bp band using DNAs from non-cancerous lesions in all cases and DNAs from cancerous lesions in 22 cases after HhaI digestion. In 10 breast cancer cases, however, the PCR amplified a 259 bp band using HhaI-digested DNA purified from only cancer tissues (Fig. 3 and Table I). Using DNA samples from the MCF7 cell line, the PCR failed to amplify the 259 bp band after HhaI digestion (Fig. 3).

Results of immunohistochemical studies and histological nuclear grade. All immunohistochemical findings are summarized in Table I. Using Ab-1 antibody, immunoreactivity for BRCA1 was observed in cell nuclei of normal mammary ducts and glands. In breast cancer cells, BRCA1 immunoreactivity was also seen in cancer cell nuclei and the intensity varied from completely negative to strongly positive (Fig. 4, a and b). According to the criteria for BRCA1 immunohistochemical evaluation, 18 of 32 breast cancers (56%) were evaluated as positive for BRCA1 expression. The immunoreactivity for ER, p53, p21 and p27 was exclusively seen in breast cancer nuclei and the frequencies of immunopositivity for these parameters were 59%, 34%, 47% and 69%, respectively. However, immu-
noreactivity for cyclin D1 and p16 was observed in both the cytoplasm and nuclei of the tumor cells with frequencies of 56% and 50%, respectively.

Of 32 breast cancers, 15 were evaluated as histological nuclear grade 3, and the remaining ones were composed of 13 cancers with nuclear grade 2 and two with nuclear grade 1.

Relation among BRCA1 methylation, its expression, the status of ER, and various cell cycle associated proteins and the morphological nuclear grade As shown in Table I, BRCA1 methylation was inversely related to its expression in breast cancer cases investigated in this study ($P=0.043$). According to the combination of BRCA1 methylation and its expression, breast cancer cases were roughly subdivided into three groups: the first group was positive for BRCA1 methylation and negative for BRCA1 expression, the second was negative for BRCA1 methylation and positive for BRCA1 expression and the third was negative for both BRCA1 methylation and its expression. However, three exceptional cancers in the first group were positive for BRCA1 methylation and expression. Breast cancers negative for BRCA1 methylation tended to contain less atypical nuclei than nuclear grade 2, and a similar tendency was observed in breast cancers with BRCA1 expression. Moreover, BRCA1 methylation was related to the expression of p21 and inversely related to p27 expression, and BRCA1 expression was related to ER expression ($P=0.011$, 0.018 and 0.016, respectively). The status of cyclin D1 and p16 expressions showed an inverse relation, but p53 expression showed no significant relationship with

Table I. Methylation Status of the BRCA1 Promoter Region and Immunohistochemical Expression of BRCA1, p21, p53, p27, ER, Cyclin D1, p16 and Nuclear Grade

| Case number | Methylation of the BRCA1 | BRCA1 expression | p53 | p21 | p27 | ER | Cyclin D1 | p16 | Histology/nuclear grade |
|-------------|--------------------------|------------------|-----|-----|-----|----|-----------|-----|------------------------|
| 1           | +                        | −                | −   | +   | +   | +  | +         | +   | IDC3                   |
| 2           | +                        | −                | −   | +   | +   | +  | +         | +   | IDC3                   |
| 3           | +                        | −                | −   | +   | ++  | −  | −         | +   | IDC3                   |
| 4           | +                        | −                | +   | −   | −   | −  | −         | +   | IDC3                   |
| 5           | +                        | −                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 6           | +                        | −                | −   | −   | −   | −  | +         | +   | IDC2                   |
| 7           | +                        | −                | −   | −   | −   | +  | −         | +   | IDC2                   |
| 8           | +                        | −                | −   | −   | −   | +  | −         | +   | IDC2                   |
| 9           | +                        | −                | −   | −   | −   | +  | −         | +   | IDC2                   |
| 10          | +                        | −                | −   | −   | −   | −  | +         | −   | IDC3                   |
| 11          | −                        | +                | −   | +   | +   | −  | −         | +   | IDC3                   |
| 12          | −                        | +                | +   | +   | −   | +  | +         | −   | IDC3                   |
| 13          | −                        | +                | −   | −   | −   | +  | +         | +   | IDC3                   |
| 14          | −                        | +                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 15          | −                        | +                | −   | +   | +   | −  | −         | +   | IDC3                   |
| 16          | −                        | +                | −   | +   | ++  | −  | −         | +   | IDC3                   |
| 17          | −                        | +                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 18          | −                        | +                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 19          | −                        | +                | +   | −   | −   | +  | −         | +   | IDC3                   |
| 20          | −                        | +                | +   | +   | −   | −  | −         | +   | IDC3                   |
| 21          | −                        | +                | +   | −   | −   | +  | −         | +   | IDC3                   |
| 22          | −                        | +                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 23          | −                        | +                | +   | −   | −   | +  | −         | +   | IDC3                   |
| 24          | −                        | +                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 25          | −                        | +                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 26          | −                        | +                | −   | +   | +   | −  | −         | +   | IDC3                   |
| 27          | −                        | +                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 28          | −                        | +                | −   | −   | −   | +  | −         | +   | IDC3                   |
| 29          | −                        | −                | −   | −   | −   | +  | +         | +   | IDC3                   |
| 30          | −                        | −                | −   | −   | −   | +  | +         | +   | IDC3                   |
| 31          | −                        | −                | −   | −   | −   | +  | +         | +   | IDC2                   |
| 32          | −                        | −                | −   | −   | −   | +  | +         | +   | IDC2                   |

++, strongly positive; +, positive; −, negative; IDC, invasive ductal carcinoma.
BRCA1 methylation or expression, or with the expression of other cell cycle regulatory proteins.

DISCUSSION

Although BRCA1 mutations are responsible for nearly half of familial breast cancers, BRCA1 mutation is rarely detected in sporadic breast cancers or is only rarely found in ovarian cancers.7,9 However, BRCA1 expression has been reported to be markedly reduced in sporadic breast cancers, suggesting that BRCA1 expression might be down-regulated by mechanisms other than point mutation. In 1997, Dobrovic and Simpfendorfer first reported hypermethylation of the BRCA1 gene in two of 7 sporadic breast cancers using Southern blot analysis after methylation-sensitive restriction enzyme treatment.15 In a large group of sporadic breast cancers, Catteau et al. found the frequency of BRCA1 methylation to be 11% using Southern blot analysis.22 In 1998, aberrant CpG methylation within the 5′ regulatory region of the BRCA1 gene was confirmed by new methodology using PCR amplification and sequencing after sodium bisulfate modification.16,23 Moreover, Mancini et al. reported that CpG methylation of the BRCA1 gene was tumor-specific and was located in a putative CREB binding site of the gene.16 In the present study using molecular biological techniques different from Southern blot hybridization, BRCA1 methylation was detected in 10 (31%) of 32 sporadic breast cancers, which is the highest frequency so far reported.

However, the BRCA1 mRNA levels were significantly down-regulated in sporadic breast cancers compared with normal breast tissues.8,17 To clarify the expression of the BRCA1 gene at the protein level in sporadic breast cancers, several immunohistochemical studies have been performed,2,24,25 but no conclusion has yet been drawn. Even the subcellular localization of the BRCA1 protein is still controversial, i.e., whether it is localized in the cytoplasm or in nuclei of normal and neoplastic breast tissues. In 1998, Jarvis et al. reported that loss of nuclear BRCA1 expression in breast cancers is associated with a more aggressive tumor phenotype.25 Very recently, Wilson et al. comprehensively characterized 19 anti-BRCA1 antibodies and concluded that Ab-1 antibody is the only reliable antibody when working on paraffin sections with antigen retrieval and an amplified staining procedure. According to their immunohistochemical study using various antibodies for BRCA1, immunoreactivity specific for BRCA1 is likely to be localized exclusively in the nuclei of normal and neoplastic breast tissues. Of 79 formalin-fixed, paraffin-embedded breast cancers, 52 tumors (65.8%) were positively stained using Ab-1 antibody for BRCA1. Our immunohistochemical findings using 32 paraffin-embedded breast cancers and Ab-1 antibody corroborate Wilson’s report.24 In addition, a previous study attempted to detect BRCA1 immunoreactivity using paraffin sections and commercially available antibodies (D-20, C-20 and 17F8), but the immunohistochemical findings were unreliable, unstable and inconclusive (data not shown).

Magdinier et al. attempted to detect the relationship between BRCA1 methylation and its expression in 37 sporadic breast cancers. They found marked down-regulation of BRCA1 mRNA, but failed to detect any hypermethylation patterns in the BRCA1 gene.17 Using breast cancer cell lines, Rice et al. reported decreased BRCA1 mRNA owing to aberrant methylation of the BRCA1 CpG island promoter.25 Our study first revealed the inverse relationship between BRCA1 methylation and its expression in a large sample of sporadic breast cancers. As shown in

Fig. 4. Immunohistochemistry for BRCA1 in sporadic breast cancers. a) Most tumor cells showed diffuse nuclear staining for Ab-1 (case No. 13). ABC method ×400. b) None of the tumor cells showed immunoreactivity for Ab-1 (case No. 4). Many mitotic figures are apparent. ABC method ×400.
Table I. Sporadic breast cancers can be subdivided into three groups according to the status of BRCA1 methylation and its expression. In the first group, expression of the BRCA1 gene is down-regulated by hypermethylation of the putative promoter region, as in tumor suppressor genes such as Rb, p16, p15 and VHL. Exceptionally, three cancers were positive for both BRCA1 methylation and its expression, but this phenomenon may be explained by differences of aberrant CpG methylation in the promoter region. In the second group, the BRCA1 gene was biologically intact. In the third group, point mutation of the BRCA1 gene may be responsible for decreasing BRCA1 expression, as seen in familial breast cancers. However, BRCA1 somatic mutations are rarely found in sporadic breast cancers, so that other mechanisms may account for the reduced expression of the BRCA1 gene. Recently, Ozcelik et al. reported that deletion at the BRCA1 locus and preferential allelic expression were observed in some sporadic breast cancers with low BRCA1 mRNA levels. It remains for future investigations to clarify the true mechanisms that reduce or silence BRCA1 expression in the third breast cancer group.

Several previous studies have revealed that decreased BRCA1 expression is closely related to highly proliferative or aggressive phenotypes in sporadic breast cancers. In invasive ductal carcinomas, Wilson et al. have clearly shown a significant inverse relationship between immunohistochemical grades of BRCA1 expression and histopathological grades of cancers. Comparing the state of BRCA1 methylation and its expression with nuclear grade of cancer cells in this study, we found that decreased BRCA1 expression in cancer cells is closely related to higher tumor nuclear grade, which corroborates previous reports.

In breast cancers, the majority of aggressive tumors is also devoid of ER expression. Evidence for estrogen regulation of BRCA1 is obvious in the mammary gland during puberty, pregnancy and lactation. Recent advances in molecular endocrinology have revealed that estrogen may regulate BRCA1 expression via protein-protein interaction between ER and the c-Fos-Jun complex at the AP1 site, because there are many transcriptional regulatory sites, including the AP1 binding site, in the BRCA1 promoter region. Therefore, it is reasonable that several studies, including the present study, show related changes of expression of the BRCA1 and ER genes in sporadic breast cancers.

BRCA1 is a putative tumor suppressor protein and is known to be expressed and phosphorylated in a cell cycle-dependent manner, suggesting that BRCA1 might be closely associated with cell cycle regulation. In the present study, the possible relationship between BRCA1 and several cell cycle regulatory proteins was investigated. The findings of the present study show that BRCA1 methylation tends to be proportionally and inversely related to p27 and p21, respectively. From the viewpoint of cell cycle arrest for breast cancers, the associated expression of BRCA1 and p27 reflects less aggressive phenotypes. The relationship between BRCA1 methylation and decreased expression of p27 in this study might reflect BRCA1 participation in cell cycle regulation by Cdk inhibitors. However, p21 expression has been frequently found in breast cancers with BRCA1 methylation. In sporadic breast tumors, Sourvinos and Spandidos have already shown that decreased BRCA1 expression levels are associated with over-expression of both p21 and MDM-2, which results in up-regulation of p21, leading to cell cycle arrest of tumor cells. The present study failed to find relationships between BRCA1, p53, cyclin D1 and p16, but an inverse relationship between cyclin D1 and p16 expression was clearly demonstrated, as previously reported. More studies are necessary to clarify the relationship between BRCA1 and Cdk inhibitors.

In conclusion, the present study confirms that the BRCA1 promoter region is abnormally methylated in sporadic breast cancers and an inverse correlation was found between methylation and protein expression of BRCA1. Moreover, decreased BRCA1 expression is closely related to the aggressive phenotype of sporadic breast cancers.

ACKNOWLEDGMENTS

This study was partly supported by Grants-in-Aid from the Kawano Memorial Foundation for Promotion of Pediatrics, Kawagoe, Saitama Pref., Japan. We thank Prof. Y. Iino and Dr. K. Iijima and their colleagues (Emergency and Critical Care Medicine and Second Dept. of Surgery, Gunma University Hospital, Maebashi, Gunma), Dr. H. Sugimoto (Dept. of Biochemistry, Gunma University School of Medicine) and Dr. T. Motojima (Motojima General Hospital, Ohta, Gunma) for guidance and assistance, including the supply of fresh specimens of breast tumors. We also thank our colleagues and technicians of the Second Dept. of Pathology, Gunma University School of Medicine for their help.

(Received October 7, 1999/Revised March 1, 2000/Accepted March 8, 2000)

REFERENCES

1) Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Lie, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bogden, R., Dayanath,
13) Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nauyen, T., Beart, R. W., Van-Tornout, J. M. and Jones, P. A. Methylation of 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55, 4531–4535 (1995).

14) Kashiwabara, K., Oyama, T., Sano, T., Fukuda, T. and Nakajima, T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb protein in primary non-small cell lung cancers. Int. J. Cancer, 79, 215–220 (1998).

15) Dobrovic, A. and Simpfendorfer, D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res., 57, 3347–3350 (1997).

16) Mancini, D. N., Rodenheimer, D. I., Ainsworth, P. J., O’Malley, F. P., Singh, S. M., Xing, W. and Archer, T. K. CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene, 16, 1161–1169 (1998).

17) Magdinier, F., Ribieras, S., Lenoir, G. M., Frappart, L. and橙子. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem. Biophys. Res. Commun., 245, 75–80 (1998).

18) Souvinos, G. and Spandidos, D. A. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem. Biophys. Res. Commun., 245, 75–80 (1998).

19) Freedman, L. S., Edwards, D. N., McConnell, E. M. and Downham, D. Y. Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br. J. Cancer, 40, 53–55 (1979).

20) Leu, W., Krill, D., Dhir, R., Becich, M. J., Dong, J.-T., Frierson, H. F., Jr., Isaacs, W. B., Isaacs, J. T. and Gao, A. C. Methylation of CD44 metastasis suppressor gene in human prostate cancer. Cancer Res., 59, 2329–2331 (1999).

21) Catto, A., Harris, W. H., Xu, C.-F. and Solomon, E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene, 18, 1957–1965 (1999).

22) Rice, J. C., Massey-Brown, K. S. and Futschek, B. W. Aberrant methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene, 17, 1807–1812 (1998).

23) Wilson, C. A., Ramos, L., Villasenor, M. R., Anders, K. H., Rress, M. F., Clarke, K., Karlan, B., Chen, J. J., Scully, R., Livingston, D. M., Zuch, R. H., Kanter, M. H., Cohen, S., Alzono, F. J. and Slamon, D. J. Localization of human BRCA1 and its loss in high-grade non-inherited breast carcinomas. Nat. Genet., 21, 236–240 (1999).

24) Jarvis, E. M., Kirk, J. A. and Clarke, C. L. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet. Cyto-
genet., 101, 109–115 (1998).
26) Ozcelik, H., To, M. D., Couture, J., Bull, S. B. and Andrulis, I. L. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int. J. Cancer, 77, 1–6 (1998).
27) Johannsson, O. T., Idvall, I., Anderson, C., Borg, Å., Barkardottir, R. B., Egilsson, V. and Olsson, H. Tumor biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer, 33, 362–371 (1997).
28) Xu, C. F., Chambers, J. A. and Solomon, E. Complex regulation of the BRCA1 gene. J. Biol. Chem., 272, 20994–20997 (1997).
29) Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, Y., Peng, Y., Zhang, H., Wu, G. S., Licht, J. D., Weber, B. L. and Ei-Deiry, W. S. Arrest of the cell cycle by the tumor-suppressor BRCA1 requires the CDK-inhibitor p21^{WAF1/CIP1}. Nature, 389, 187–190 (1997).
30) Malusecka, E., Zborek, A. and Kuzyzowska-Gruca, S. Changes in expression of pRb, p16 and cyclin D1 in non-small cell lung cancer: an immunohistochemical study. Folia Histochem. Cytobiol., 37, 19–24 (1999).
31) Dublin, F., Patel, N. K., Gillett, C. E., Smith, P., Peters, G. and Barnes, D. M. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int. J. Cancer, 79, 71–75 (1998).